This event has ended.
Sweden is one of the most innovative countries in the world and a global leader in the health and life sciences sector. With ambitions to be a world leader in ATMP development by 2030, the country
benefits from a thriving biotechnology network and national initiatives coordinated by ATMP Sweden.
In May 2023 the Swedish government, through Vinnova, the Swedish Innovation Agency, announced a 160 million SEK budget to establish several national clusters for the commercialisation of advanced therapies, such as The Centre for Commercialisation of Regenerative Medicine, CCRM Nordic, which will be located in “GoCo”, Gothenburg’s Health Innovation City.
In 2022, the UK and Sweden signed a joint Memorandum of Understanding on health and life sciences, highlighting ATMP as a priority. Opportunities for UK-Swedish ATMP
collaboration and partnerships are significant.
FOCUS TECHNOLOGIES:
Innovative and sustainable biomanufacturing processes and process technologies that enable the development of ATMP and delivery systems. Including but not limited to:
• Manufacturing of cell therapies such as stem cell, natural killer (NK) cells, Tcell, and other engineered cell therapies
• Manufacturing of gene therapies using viral, and non-viral vectors
• mRNA and viral vector-based vaccine manufacturing
• Manufacturing of regenerative medicine
• Development of personalised medicines
benefits from a thriving biotechnology network and national initiatives coordinated by ATMP Sweden.
In May 2023 the Swedish government, through Vinnova, the Swedish Innovation Agency, announced a 160 million SEK budget to establish several national clusters for the commercialisation of advanced therapies, such as The Centre for Commercialisation of Regenerative Medicine, CCRM Nordic, which will be located in “GoCo”, Gothenburg’s Health Innovation City.
In 2022, the UK and Sweden signed a joint Memorandum of Understanding on health and life sciences, highlighting ATMP as a priority. Opportunities for UK-Swedish ATMP
collaboration and partnerships are significant.
FOCUS TECHNOLOGIES:
Innovative and sustainable biomanufacturing processes and process technologies that enable the development of ATMP and delivery systems. Including but not limited to:
• Manufacturing of cell therapies such as stem cell, natural killer (NK) cells, Tcell, and other engineered cell therapies
• Manufacturing of gene therapies using viral, and non-viral vectors
• mRNA and viral vector-based vaccine manufacturing
• Manufacturing of regenerative medicine
• Development of personalised medicines
- Company mission
- -
- Stockholm, Sweden
Practical information
- Where
- Sweden
- When
- -
- Host organisation
- GWE Business West Ltd
- Website
- https://advanced-therapies-opportunities-for-uk.b2match.io/
Description
Innovate UK is inviting ambitious companies to participate in the Global Business Innovation
Programme. Delivered by Innovate UK EDGE, the programme consists of a preparation
phase, followed by a 5-day tailored visit to Sweden with the opportunity to meet and collaborate with key stakeholders and experts developing Advanced Therapy Medicinal Products (ATMP). The programme will provide a unique experience for delegates to identify international partners for
technology collaboration.
B2B meetings are scheduled for UK-Swedish companies on the 24-25th January 2024. Long-term matchmaking via the website will also be available.
Programme. Delivered by Innovate UK EDGE, the programme consists of a preparation
phase, followed by a 5-day tailored visit to Sweden with the opportunity to meet and collaborate with key stakeholders and experts developing Advanced Therapy Medicinal Products (ATMP). The programme will provide a unique experience for delegates to identify international partners for
technology collaboration.
B2B meetings are scheduled for UK-Swedish companies on the 24-25th January 2024. Long-term matchmaking via the website will also be available.